Rauner, Martina
Martina Rauner researcher (ORCID 0000-0002-4067-6799)
VIAF ID: 8186158675974327500006 (Personal)
Permalink: http://viaf.org/viaf/8186158675974327500006
Preferred Forms
- 100 0 _ ‡a Martina Rauner ‡c researcher (ORCID 0000-0002-4067-6799)
- 100 1 _ ‡a Rauner, Martina
- 100 1 _ ‡a Rauner, Martina
4xx's: Alternate Name Forms (1)
5xx's: Related Names (2)
Works
Title | Sources |
---|---|
The anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1. | |
Author Correction: Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signaling | |
Cellular Spatiotemporal Dynamics During Skeletal Regeneration in Axolotl | |
Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer | |
Dickkopf1 fuels inflammatory cytokine responses | |
Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, compound A, in human bone marrow stromal cells. | |
The effect of the degree of sulfation of glycosaminoglycans on osteoclast function and signaling pathways | |
Endocrine and clinical correlates of myostatin serum concentration in men--the STRAMBO study. | |
Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway | |
Erythropoietin Mediated Bone Loss in Mice Is Dose-Dependent and Mostly Irreversible | |
Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. | |
Increased EPO Levels Are Associated With Bone Loss in Mice Lacking PHD2 in EPO-Producing Cells | |
Inhibition of lamin A/C attenuates osteoblast differentiation and enhances RANKL-dependent osteoclastogenesis | |
The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss | |
Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide | |
miR-125b regulates calcification of vascular smooth muscle cells | |
NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis | |
New multifunctional nanocomposites for sustainable wastewater treatment | |
The osteoclast-associated receptor (OSCAR) is a novel receptor regulated by oxidized low-density lipoprotein in human endothelial cells. | |
Osteocyte apoptosis and cellular micropetrosis signify skeletal aging in type 1 diabetes | |
Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking the transcription factor NFATc2. | |
Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis | |
The promotion of osteoclastogenesis by sulfated hyaluronan through interference with osteoprotegerin and receptor activator of NF-κB ligand/osteoprotegerin complex formation | |
Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. | |
Stimulation of bone formation by monocyte-activator functionalized graphene oxide in vivo | |
Structural and functional insights into sclerostin-glycosaminoglycan interactions in bone | |
WNT5A has anti-prostate cancer effects in vitro and reduces tumor growth in the skeleton in vivo | |
Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors | |
WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production |